The clinical utility of C-peptide measurement in the care of patients with diabetes

Diabetic Medicine

Volumn 30, Issue 7, 2013, Pages 803-817

  Jones, A G ^a,b   Hattersley, A T ^a,b  

^a UNIVERSITY OF EXETER MEDICAL SCHOOL   (United Kingdom)

^b ROYAL DEVON AND EXETER NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; CREATININE; EDETIC ACID; GLUCAGON; INSULIN; PROINSULIN;

ASSAY; CENTRIFUGATION; CREATININE URINE LEVEL; CROSS REACTION; DIABETES MELLITUS; DIABETIC KETOACIDOSIS; DISEASE CLASSIFICATION; FIRST PASS EFFECT; FLUORESCENCE ANALYSIS; FREEZING; GLOMERULUS FILTRATION; HALF LIFE TIME; HUMAN; IMMUNOASSAY; INSULIN DEFICIENCY; INSULIN DEPENDENCE; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PATIENT CARE; PREDICTIVE VALUE; PROTEIN BLOOD LEVEL; PROTEIN METABOLISM; PROTEIN STABILITY; PROTEIN URINE LEVEL; RADIOIMMUNOASSAY; REFERENCE VALUE; REVIEW; ROOM TEMPERATURE; STANDARDIZATION; SYSTEMATIC REVIEW; SYSTEMIC CIRCULATION; TREATMENT RESPONSE;

C-PEPTIDE; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; HUMANS; INSULIN; INSULIN RESISTANCE; PROGNOSIS;

EID: 84879570186     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/dme.12159     Document Type: Review

References (132)

1. Wahren J, Kallas A, Sima AA. The clinical potential of C-peptide replacement in type 1 diabetes. Diabetes 2012; 61: 761-772.
2. Cryer PE, Axelrod L, Grossman AB, Heller SR, Montori VM, Seaquist ER et al. Evaluation and management of adult hypoglycemic disorders: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2009; 94: 709-728.
3. Brandenburg D. History and diagnostic significance of C-peptide. Exp Diabetes Res 2008; 2008: 576862.
4. Clark PM. Assays for insulin, proinsulin(s) and C-peptide. Ann Clin Biochem 1999; 36: 541-564.
5. Polonsky KS, Licinio-Paixao J, Given BD, Pugh W, Rue P, Galloway J et al. Use of biosynthetic human C-peptide in the measurement of insulin secretion rates in normal volunteers and type I diabetic patients. J Clin Invest 1986; 77: 98-105.
6. Licinio-Paixao J, Polonsky KS, Given BD, Pugh W, Ostrega D, Frank BF et al. Ingestion of a mixed meal does not affect the metabolic clearance rate of biosynthetic human C-peptide. J Clin Endocrinol Metab 1986; 63: 401-403.
7. Field JB. Extraction of insulin by liver. Annu Rev Med 1973; 24: 309-314.
8. Brundin T. Splanchnic and extrasplanchnic extraction of insulin following oral and intravenous glucose loads. Clin Sci (Lond) 1999; 97: 429-436.
9. Shapiro ET, Tillil H, Rubenstein AH, Polonsky KS. Peripheral insulin parallels changes in insulin secretion more closely than C-peptide after bolus intravenous glucose administration. J Clin Endocrinol Metab 1988; 67: 1094-1099.
10. Eaton RP, Allen RC, Schade DS, Erickson KM, Standefer J. Prehepatic insulin production in man: kinetic analysis using peripheral connecting peptide behavior. J Clin Endocrinol Metab 1980; 51: 520-528.
11. Van Cauter E, Mestrez F, Sturis J, Polonsky KS. Estimation of insulin secretion rates from C-peptide levels. Comparison of individual and standard kinetic parameters for C-peptide clearance. Diabetes 1992; 41: 368-377.
12. Henriksen JH, Tronier B, Bulow JB. Kinetics of circulating endogenous insulin, C-peptide, and proinsulin in fasting nondiabetic man. Metabolism 1987; 36: 463-468.
13. Zavaroni I, Deferrari G, Lugari R, Bonora E, Garibotto G, Dall'Aglio E et al. Renal metabolism of C-peptide in man. J Clin Endocrinol Metab 1987; 65: 494-498.
14. Covic AM, Schelling JR, Constantiner M, Iyengar SK, Sedor JR. Serum C-peptide concentrations poorly phenotype type 2 diabetic end-stage renal disease patients. Kidney Int 2000; 58: 1742-1750.
15. Abe M, Okada K, Matsumoto K. Plasma insulin and C-peptide concentrations in diabetic patients undergoing hemodialysis: comparison with five types of high-flux dialyzer membranes. Diabetes Res Clin Pract 2008; 82: e17-19.
16. Faradji RN, Monroy K, Messinger S, Pileggi A, Froud T, Baidal DA et al. Simple measures to monitor beta-cell mass and assess islet graft dysfunction. Am J Transplant 2007; 7: 303-308.
17. Gale EA. Latent autoimmune diabetes in adults: a guide for the perplexed. Diabetologia 2005; 48: 2195-2199.
18. Thunander M, Torn C, Petersson C, Ossiansson B, Fornander J, Landin-Olsson M. Levels of C-peptide, BMI, and age, and their utility for classification of diabetes in relation to autoimmunity, in adults with newly diagnosed diabetes in Kronoberg, Sweden. Eur J Endocrinol 2012; 166: 1021-1029.
19. Redondo MJ, Rodriguez LM, Escalante M, O'Brian Smith E, Balasubramanyam A, Haymond MW. Beta cell function and BMI in ethnically diverse children with newly diagnosed autoimmune type 1 diabetes. Pediatr Diabetes 2012; 13: 564-571.
20. Winter WE, Schatz DA. Autoimmune markers in diabetes. Clin Chem 2011; 57: 168-175.
21. Ashby JP, Frier BM. Circulating C peptide: measurement and clinical application. Ann Clin Biochem 1981; 18: 125-130.
22. Koskinen P. Nontransferability of C-peptide measurements with various commercial radioimmunoassay reagents. Clin Chem 1988; 34: 1575-1578.
23. Palmer JP, Fleming GA, Greenbaum CJ, Herold KC, Jansa LD, Kolb H et al. C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001. Diabetes 2004; 53: 250-264.
24. Little RR, Rohlfing CL, Tennill AL, Madsen RW, Polonsky KS, Myers GL et al. Standardization of C-peptide measurements. Clin Chem 2008; 54: 1023-1026.
25. Wiedmeyer HM, Polonsky KS, Myers GL, Little RR, Greenbaum CJ, Goldstein DE et al. International comparison of C-peptide measurements. Clin Chem 2007; 53: 784-787.
26. Bolner A, Lomeo L, Lomeo AM. 'Method-specific' stability of serum C-peptide in a multicenter clinical study. Clin Lab 2005; 51: 153-155.
27. McDonald TJ, Perry MH, Peake RW, Pullan NJ, O'Connor J, Shields BM et al. EDTA improves stability of whole blood C-Peptide and insulin to over 24 hours at room temperature. PLoS One 2012; 7: e42084.
28. Oddoze C, Lombard E, Portugal H. Stability study of 81 analytes in human whole blood, in serum and in plasma. Clin Biochem 2012; 45: 464-469.
29. Jane Ellis M, Livesey JH, Evans MJ. Hormone stability in human whole blood. Clin Biochem 2003; 36: 109-112.
30. Albareda M, Rigla M, Rodriguez-Espinosa J, Caballero A, Chico A, Cabezas R et al. Influence of exogenous insulin on C-peptide levels in subjects with type 2 diabetes. Diabetes Res Clin Pract 2005; 68: 202-206.
31. Nosari I, Lepore G, Maglio ML, Cortinovis F, Pagani G. The effect of various blood glucose levels on post-glucagon C-peptide secretion in type 2 (non insulin-dependent) diabetes. J Endocrinol Invest 1992; 15: 143-146.
32. Hsieh SD, Iwamoto Y, Matsuda A, Kuzuya T. Pancreatic B-cell function in non-insulin-dependent diabetes mellitus during successive periods of sulfonylurea and insulin treatment: serum C-peptide response to glucagon and urine C-peptide excretion. Endocrinol Jpn 1987; 34: 561-567.
33. Aoki Y. Variation of endogenous insulin secretion in association with treatment status: assessment by serum C-peptide and modified urinary C-peptide. Diabetes Res Clin Pract 1991; 14: 165-173.
34. Greenbaum CJ, Mandrup-Poulsen T, McGee PF, Battelino T, Haastert B, Ludvigsson J et al. Mixed-meal tolerance test versus glucagon stimulation test for the assessment of beta-cell function in therapeutic trials in type 1 diabetes. Diabetes Care 2008; 31: 1966-1971.
35. Gjessing HJ, Matzen LE, Froland A, Faber OK. Correlations between fasting plasma C-peptide, glucagon-stimulated plasma C-peptide, and urinary C-peptide in insulin-treated diabetics. Diabetes Care 1987; 10: 487-490.
36. Laakso M, Ronnemaa T, Sarlund H, Pyorala K, Kallio V. Factors associated with fasting and postglucagon plasma C-peptide levels in middle-aged insulin-treated diabetic patients. Diabetes Care 1989; 12: 83-88.
37. Besser RE, Jones AG, McDonald TJ, Shields BM, Knight BA, Hattersley AT. The impact of insulin administration during the mixed meal tolerance test. Diabet Med 2012; 29: 1279-1284.
38. Torn C L-OM, Schersten B. Predictability of C-peptide for autoimmune diabetes in young adult diabetic patients. Pract Diabetes Int 2001; 18: 83-88.
39. Berger B, Stenstrom G, Sundkvist G. Random C-peptide in the classification of diabetes. Scand J Clin Lab Invest 2000; 60: 687-693.
40. Lee A, Morley J. Classification of type 2 diabetes by clinical response to metformin-troglitazone combination and C-peptide criteria. Endocr Pract 1999; 5: 305-313.
41. Prior MJ, Prout T, Miller D, Ewart R, Kumar D. C-peptide and the classification of diabetes mellitus patients in the Early Treatment Diabetic Retinopathy Study. Report number 6. The ETDRS Research Group. Ann Epidemiol 1993; 3: 9-17.
42. Meier JJ, Menge BA, Breuer TG, Muller CA, Tannapfel A, Uhl W et al. Functional assessment of pancreatic beta-cell area in humans. Diabetes 2009; 58: 1595-1603.
43. Festa A, Williams K, Hanley AJ, Haffner SM. Beta-cell dysfunction in subjects with impaired glucose tolerance and early type 2 diabetes: comparison of surrogate markers with first-phase insulin secretion from an intravenous glucose tolerance test. Diabetes 2008; 57: 1638-1644.
44. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 2004; 27: 1487-1495.
45. Gjessing HJ, Damsgaard EM, Matzen LE, Faber OK, Froland A. The beta-cell response to glucagon and mixed meal stimulation in non-insulin dependent diabetes. Scand J Clin Lab Invest 1988; 48: 771-777.
46. Gjessing HJ, Reinholdt B, Pedersen O. The plasma C-peptide and insulin responses to stimulation with intravenous glucagon and a mixed meal in well-controlled type 2 (non-insulin-dependent) diabetes mellitus: dependency on acutely established hyperglycaemia. Diabetologia 1989; 32: 858-863.
47. Prando R, Odetti P, Melga P, Giusti R, Ciuchi E, Cheli V. Progressive deterioration of beta-cell function in nonobese type 2 diabetic subjects. Postprandial plasma C-peptide level is an indication of insulin dependency. Diabetes Metab 1996; 22: 185-191.
48. Umpaichitra V, Bastian W, Taha D, Banerji MA, AvRuskin TW, Castells S. C-peptide and glucagon profiles in minority children with type 2 diabetes mellitus. J Clin Endocrinol Metab 2001; 86: 1605-1609.
49. Marena S, Montegrosso G, De Michieli F, Pisu E, Pagano G. Comparison of the metabolic effects of mixed meal and standard oral glucose tolerance test on glucose, insulin and C-peptide response in healthy, impaired glucose tolerance, mild and severe non-insulin-dependent diabetic subjects. Acta Diabetol 1992; 29: 29-33.
50. Horwitz DL, Rubenstein AH, Katz AI. Quantitation of human pancreatic beta-cell function by immunoassay of C-peptide in urine. Diabetes 1977; 26: 30-35.
51. McDonald TJ, Knight BA, Shields BM, Bowman P, Salzmann MB, Hattersley AT. Stability and reproducibility of a single-sample urinary C-peptide/creatinine ratio and its correlation with 24-h urinary C-peptide. Clin Chem 2009; 55: 2035-2039.
52. Huttunen NP, Knip M, Kaar ML, Puukka R, Akerblom HK. Clinical significance of urinary C-peptide excretion in children with insulin-dependent diabetes mellitus. Acta Paediatr Scand 1989; 78: 271-277.
53. Lindstrom T, Arnqvist HJ, Ludvigsson J, von Schenck HH. C-peptide profiles in patients with non-insulin-dependent diabetes mellitus before and during insulin treatment. Acta Endocrinol (Copenh) 1992; 126: 477-483.
54. Meistas MT, Rendell M, Margolis S, Kowarski AA. Estimation of the secretion rate of insulin from the urinary excretion rate of C-peptide. Study in obese and diabetic subjects. Diabetes 1982; 31: 449-453.
55. Gero L, Koranyi L, Tamas G Jr. Residual B-cell function in insulin dependent (Type 1) and non insulin-dependent (Type 2) diabetics (relationship between 24-hour C-peptide excretion and the clinical features of diabetes). Diabetes Metab 1983; 9: 183-187.
56. Garvey WT, Olefsky JM, Rubenstein AH, Kolterman OG. Day-long integrated serum insulin and C-peptide profiles in patients with NIDDM. Correlation with urinary C-peptide excretion. Diabetes 1988; 37: 590-599.
57. Sabot O, Tourniaire J, Charrie A, Rebattu B, Jouve M, Ayzac L et al. Dosages du C-peptide urinaire et plasmatique de base et sous stimulation par le glucagon chez des sujets sains ou diabétiques (C-peptide assays of the urine and plasma at baseline and under stimulation with glucagon in healthy subjects and diabetics). Presse Med 1990; 19: 860-863.
58. Tillil H, Shapiro ET, Given BD, Rue P, Rubenstein AH, Galloway JA et al. Reevaluation of urine C-peptide as measure of insulin secretion. Diabetes 1988; 37: 1195-1201.
59. Fernandez-Castaner M, Rosel P, Ricart W, Montana E, Gomez JM, Navarro MA et al. Evaluation of B-cell function in diabetics by C-peptide determination in basal and postprandial urine. Diabetes Metab 1987; 13: 538-542.
60. Wasada T, Kuroki H, Arii H, Maruyama A, Katsumori K, Aoki K et al. Hyperglycemia facilitates urinary excretion of C-peptide by increasing glomerular filtration rate in non-insulin-dependent diabetes mellitus. Metabolism 1995; 44: 1194-1198.
61. Hsieh SD, Iwamoto Y, Matsuda A, Kuzuya T. Reduction in urine C-peptide clearance rate after metabolic control in NIDDM patients. Endocrinol Jpn 1988; 35: 601-606.
62. Jones AG, Besser RE, McDonald TJ, Shields BM, Hope SV, Bowman P et al. Urine C-peptide creatinine ratio is an alternative to stimulated serum C-peptide measurement in late-onset, insulin-treated diabetes. Diabet Med 2011; 28: 1034-1038.
63. Besser RE, Ludvigsson J, Jones AG, McDonald TJ, Shields BM, Knight BA et al. Urine C-peptide creatinine ratio is a noninvasive alternative to the mixed-meal tolerance test in children and adults with type 1 diabetes. Diabetes Care 2011; 34: 607-609.
64. Bowman P, McDonald TJ, Shields BM, Knight BA, Hattersley AT. Validation of a single-sample urinary C-peptide creatinine ratio as a reproducible alternative to serum C-peptide in patients with Type 2 diabetes. Diabet Med 2011; 29: 90-93.
65. Besser RE, Shepherd MH, McDonald TJ, Shields BM, Knight BA, Ellard S et al. Urinary C-peptide creatinine ratio is a practical outpatient tool for identifying hepatocyte nuclear factor 1-α/hepatocyte nuclear factor 4-α maturity-onset diabetes of the young from long-duration type 1 diabetes. Diabetes Care 2011; 34: 286-291.
66. Thomas NJ, Shields BM, Besser RE, Jones AG, Rawlingson A, Goodchild E et al. The impact of gender on urine C-peptide creatinine ratio interpretation. Ann Clin Biochem 2012; 49: 363-368.
67. Ludvigsson J, Carlsson A, Forsander G, Ivarsson S, Kockum I, Lernmark A et al. C-peptide in the classification of diabetes in children and adolescents. Pediatr Diabetes 2012; 13: 45-50.
68. Shepherd M, Shields B, Ellard S, Rubio-Cabezas O, Hattersley AT. A genetic diagnosis of HNF1A diabetes alters treatment and improves glycaemic control in the majority of insulin-treated patients. Diabet Med 2009; 26: 437-441.
69. Murphy R, Ellard S, Hattersley AT. Clinical implications of a molecular genetic classification of monogenic beta-cell diabetes. Nat Clin Pract Endocrinol Metab 2008; 4: 200-213.
70. Hattersley A, Bruining J, Shield J, Njolstad P, Donaghue K. ISPAD Clinical Practice Consensus Guidelines 2006-2007. The diagnosis and management of monogenic diabetes in children. Pediatr Diabetes 2006; 7: 352-360.
71. Thanabalasingham G, Pal A, Selwood MP, Dudley C, Fisher K, Bingley PJ et al. Systematic assessment of etiology in adults with a clinical diagnosis of young-onset Type 2 diabetes is a successful strategy for identifying maturity-onset diabetes of the young. Diabetes Care 2012; 35: 1206-1212.
72. Mazzaccara C, Iafusco D, Liguori R, Ferrigno M, Galderisi A, Vitale D et al. Mitochondrial diabetes in children: seek and you will find it. PLoS One 2012; 7: e34956.
73. Murphy R, Turnbull DM, Walker M, Hattersley AT. Clinical features, diagnosis and management of maternally inherited diabetes and deafness (MIDD) associated with the 3243A>G mitochondrial point mutation. Diabet Med 2008; 25: 383-399.
74. Gloyn AL, Pearson ER, Antcliff JF, Proks P, Bruining GJ, Slingerland AS et al. Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. N Engl J Med 2004; 350: 1838-1849.
75. The Diabetes Control and Complications Trial Research Group. Effect of intensive therapy on residual beta-cell function in patients with type 1 diabetes in the Diabetes Control and Complications Rrial. A randomized, controlled trial. Ann Intern Med 1998; 128: 517-523.
76. Steffes MW, Sibley S, Jackson M, Thomas W. Beta-cell function and the development of diabetes-related complications in the Diabetes Control and Complications Trial. Diabetes Care 2003; 26: 832-836.
77. Hoekstra JB, Van Rijn HJ, Thijssen JH, Erkelens DW. C-peptide reactivity as a measure of insulin dependency in obese diabetic patients treated with insulin. Diabetes Care 1982; 5: 585-591.
78. Rendell M. C-peptide levels as a criterion in treatment of maturity-onset diabetes. J Clin Endocrinol Metab 1983; 57: 1198-1206.
79. Madsbad S, Krarup T, McNair P, Christiansen C, Faber OK, Transbol I et al. Practical clinical value of the C-peptide response to glucagon stimulation in the choice of treatment in diabetes mellitus. Acta Med Scand 1981; 210: 153-156.
80. Matsuda A, Kamata I, Iwamoto Y, Sakamoto Y, Kuzuya T. A comparison of serum C-peptide response to intravenous glucagon, and urine C-peptide, as indexes of insulin dependence. Diabetes Res Clin Pract 1985; 1: 161-167.
81. Koskinen P, Viikari J, Irjala K, Kaihola HL, Seppala P. Plasma and urinary C-peptide in the classification of adult diabetics. Scand J Clin Lab Invest 1986; 46: 655-663.
82. Koskinen P, Viikari J, Irjala K, Kaihola HL, Seppala P. C-peptide determination in the choice of treatment in diabetes mellitus. Scand J Clin Lab Invest 1985; 45: 589-597.
83. Grant PJ, Barlow E, Miles DW. Plasma C-peptide levels identify insulin-treated diabetic patients suitable for oral hypoglycaemic therapy. Diabet Med 1984; 1: 284-286.
84. Landstedt-Hallin L, Arner P, Lins PE, Bolinder J, Olsen H, Groop L. The role of sulphonylurea in combination therapy assessed in a trial of sulphonylurea withdrawal. Scandinavian Insulin-Sulphonylurea Study Group Research Team. Diabet Med 1999; 16: 827-834.
85. Yokoyama H, Sone H, Yamada D, Honjo J, Haneda M. Contribution of glimepiride to basal-prandial insulin therapy in patients with type 2 diabetes. Diabetes Res Clin Pract 2011; 91: 148-153.
86. Nyback-Nakell A, Adamson U, Lins PE, Landstedt-Hallin L. Glycaemic responsiveness to long-term insulin plus sulphonylurea therapy as assessed by sulphonylurea withdrawal. Diabet Med 2007; 24: 1424-1429.
87. Iwao T, Sakai K, Sata M. Postprandial serum C-peptide is a useful parameter in the prediction of successful switching to liraglutide monotherapy from complex insulin therapy in Japanese patients with type 2 diabetes. J Diabetes Complications 2012; 27: 87-91.
88. Davis SN, Johns D, Maggs D, Xu H, Northrup JH, Brodows RG. Exploring the substitution of exenatide for insulin in patients with type 2 diabetes treated with insulin in combination with oral antidiabetes agents. Diabetes Care 2007; 30: 2767-2772.
89. Ferrannini E, Gastaldelli A, Miyazaki Y, Matsuda M, Mari A, DeFronzo RA. Beta-cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis. J Clin Endocrinol Metab 2005; 90: 493-500.
90. Kohnert KD, Augstein P, Zander E, Heinke P, Peterson K, Freyse EJ et al. Glycemic variability correlates strongly with postprandial beta-cell dysfunction in a segment of type 2 diabetic patients using oral hypoglycemic agents. Diabetes Care 2009; 32: 1058-1062.
91. Shapiro AM, Ricordi C, Hering BJ, Auchincloss H, Lindblad R, Robertson RP et al. International trial of the Edmonton protocol for islet transplantation. N Engl J Med 2006; 355: 1318-1330.
92. Sherr J, Tamborlane WV, Xing D, Tsalikian E, Mauras N, Buckingham B et al. Achievement of target A1C levels with negligible hypoglycemia and low glucose variability in youth with short-term type 1 diabetes and residual beta-cell function. Diabetes Care 2012; 35: 817-820.
93. Jones AG, Besser RE, Shields BM, McDonald TJ, Hope SV, Knight BA et al. Assessment of endogenous insulin secretion in insulin-treated diabetes predicts postprandial glucose and treatment response to prandial insulin. BMC Endocr Disord 2012; 12: 6.
94. Maldonado MR, Otiniano ME, Cheema F, Rodriguez L, Balasubramanyam A. Factors associated with insulin discontinuation in subjects with ketosis-prone diabetes but preserved beta-cell function. Diabet Med 2005; 22: 1744-1750.
95. Maldonado M, Hampe CS, Gaur LK, D'Amico S, Iyer D, Hammerle LP et al. Ketosis-prone diabetes: dissection of a heterogeneous syndrome using an immunogenetic and beta-cell functional classification, prospective analysis, and clinical outcomes. J Clin Endocrinol Metab 2003; 88: 5090-5098.
96. Balasubramanyam A, Garza G, Rodriguez L, Hampe CS, Gaur L, Lernmark A et al. Accuracy and predictive value of classification schemes for ketosis-prone diabetes. Diabetes Care 2006; 29: 2575-2579.
97. Landin-Olsson M, Nilsson KO, Lernmark A, Sundkvist G. Islet cell antibodies and fasting C-peptide predict insulin requirement at diagnosis of diabetes mellitus. Diabetologia 1990; 33: 561-568.
98. Hermann LS, Schersten B, Melander A. Antihyperglycaemic efficacy, response prediction and dose-response relations of treatment with metformin and sulphonylurea, alone and in primary combination. Diabet Med 1994; 11: 953-960.
99. Goto A, Takaichi M, Kishimoto M, Takahashi Y, Kajio H, Shimbo T et al. Body mass index, fasting plasma glucose levels, and C-peptide levels as predictors of the future insulin use in Japanese type 2 diabetic patients. Endocr J 2010; 57: 237-244.
100. Saisho Y, Kou K, Tanaka K, Abe T, Kurosawa H, Shimada A et al. Postprandial serum C-peptide to plasma glucose ratio as a predictor of subsequent insulin treatment in patients with type 2 diabetes. Endocr J 2011; 58: 315-322.
101. Groop LC, Pelkonen R, Koskimies S, Bottazzo GF, Doniach D. Secondary failure to treatment with oral antidiabetic agents in non-insulin-dependent diabetes. Diabetes Care 1986; 9: 129-133.
102. Cook CB, Lyles RH, El-Kebbi I, Ziemer DC, Gallina DL, Dunbar VG et al. The potentially poor response to outpatient diabetes care in urban African-Americans. Diabetes Care 2001; 24: 209-215.
103. Maldonado M, D'Amico S, Otiniano M, Balasubramanyam A, Rodriguez L, Cuevas E. Predictors of glycaemic control in indigent patients presenting with diabetic ketoacidosis. Diabetes Obes Metab 2005; 7: 282-289.
104. Chan WB, Chan JC, Chow CC, Yeung VT, So WY, Li JK et al. Glycaemic control in type 2 diabetes: the impact of body weight, beta-cell function and patient education. Q J Med 2000; 93: 183-190.
105. Nagasaka S, Aiso Y, Yoshizawa K, Ishibashi S. Comparison of pioglitazone and metformin efficacy using homeostasis model assessment. Diabet Med 2004; 21: 136-141.
106. Bluher M, Lubben G, Paschke R. Analysis of the relationship between the Pro12Ala variant in the PPAR-γ2 gene and the response rate to therapy with pioglitazone in patients with type 2 diabetes. Diabetes Care 2003; 26: 825-831.
107. Jones TA, Sautter M, Van Gaal LF, Jones NP. Addition of rosiglitazone to metformin is most effective in obese, insulin-resistant patients with type 2 diabetes. Diabetes Obes Metab 2003; 5: 163-170.
108. Kim YM, Cha BS, Kim DJ, Choi SH, Kim SK, Ahn CW et al. Predictive clinical parameters for therapeutic efficacy of rosiglitazone in Korean type 2 diabetes mellitus. Diabetes Res Clin Pract 2005; 67: 43-52.
109. Schweizer A, Dejager S, Foley JE. Impact of insulin resistance, body mass index, disease duration, and duration of metformin use on the efficacy of vildagliptin. Diabetes Ther 2012; 3: 8.
110. Kim SA, Shim WH, Lee EH, Lee YM, Beom SH, Kim ES et al. Predictive clinical parameters for the therapeutic efficacy of sitagliptin in Korean type 2 diabetes mellitus. Diabetes Metab J 2011; 35: 159-165.
111. Trischitta V, Italia S, Raimondo M, Guardabasso V, Licciardello C, Runello F et al. Efficacy of combined treatments in NIDDM patients with secondary failure to sulphonylureas. Is it predictable? J Endocrinol Invest 1998; 21: 744-747.
112. Lee WJ, Chong K, Ser KH, Chen JC, Lee YC, Chen SC et al. C-peptide predicts the remission of Type 2 diabetes after bariatric surgery. Obes Surg 2011; 22: 293-298.
113. Sjoberg S, Gunnarsson R, Gjotterberg M, Lefvert AK, Persson A, Ostman J. Residual insulin production, glycaemic control and prevalence of microvascular lesions and polyneuropathy in long-term type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1987; 30: 208-213.
114. Panero F, Novelli G, Zucco C, Fornengo P, Perotto M, Segre O et al. Fasting plasma C-peptide and micro- and macrovascular complications in a large clinic-based cohort of type 1 diabetic patients. Diabetes Care 2009; 32: 301-305.
115. Bo S, Cavallo-Perin P, Gentile L, Repetti E, Pagano G. Relationship of residual beta-cell function, metabolic control and chronic complications in type 2 diabetes mellitus. Acta Diabetol 2000; 37: 125-129.
116. Sari R, Balci MK. Relationship between C peptide and chronic complications in type-2 diabetes mellitus. J Natl Med Assoc 2005; 97: 1113-1118.
117. Inukai T, Matsutomo R, Tayama K, Aso Y, Takemura Y. Relation between the serum level of C-peptide and risk factors for coronary heart disease and diabetic microangiopathy in patients with type-2 diabetes mellitus. Exp Clin Endocrinol Diabetes 1999; 107: 40-45.
118. Mosier MA. Circulating C-peptide and diabetic retinopathy. Diabetes Res 1984; 1: 151-154.
119. Suzuki K, Watanabe K, Motegi T, Kajinuma H. High prevalence of proliferative retinopathy in diabetic patients with low pancreatic B-cell capacity. Diabetes Res Clin Pract 1989; 6: 45-52.
120. Boz M, Scheen AJ, Gerard PL, Castillo MJ, Lefebvre PJ. Retinopathy, but not neuropathy, is influenced by the level of residual endogenous insulin secretion in type 2 diabetes. Diabete Metab 1995; 21: 353-359.
121. Madsbad S, Lauritzen E, Faber OK, Binder C. The effect of residual beta-cell function on the development of diabetic retinopathy. Diabet Med 1986; 3: 42-45.
122. Klein R, Klein BE, Moss SE, Cruickshanks KJ. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XV. The long-term incidence of macular edema. Ophthalmology 1995; 102: 7-16.
123. Couper JDK. ISPAD clinical practice consensus guidelines 2009 compendium. Phases of diabetes in children and adolescents. Pediatr Diabetes 2009; 10: 13-16.
124. Rewers M, Gottlieb P. Immunotherapy for the prevention and treatment of type 1 diabetes: human trials and a look into the future. Diabetes Care 2009; 32: 1769-1782.
125. Ryan EA, Paty BW, Senior PA, Lakey JR, Bigam D, Shapiro AM. Beta-score: an assessment of beta-cell function after islet transplantation. Diabetes Care 2005; 28: 343-347.
126. Barton FB, Rickels MR, Alejandro R, Hering BJ, Wease S, Naziruddin B et al. Improvement in outcomes of clinical islet transplantation: 1999-2010. Diabetes Care 2012; 35: 1436-1445.
127. Matsuda M. Measuring and estimating insulin resistance in clinical and research settings. Nutr Metab Cardiovasc Dis 2010; 20: 79-86.
128. Sacks DB, Arnold M, Bakris GL, Bruns DE, Horvath AR, Kirkman MS et al. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin Chem 2011; 57: e1-e47.
129. Katz LE, Jawad AF, Ganesh J, Abraham M, Murphy K, Lipman TH. Fasting c-peptide and insulin-like growth factor-binding protein-1 levels help to distinguish childhood type 1 and type 2 diabetes at diagnosis. Pediatr Diabetes 2007; 8: 53-59.
130. Service FJ, Rizza RA, Zimmerman BR, Dyck PJ, O'Brien PC, Melton LJ 3rd. The classification of diabetes by clinical and C-peptide criteria. A prospective population-based study. Diabetes Care 1997; 20: 198-201.
131. Hohberg C, Pfutzner A, Forst T, Lubben G, Karagiannis E, Borchert M et al. Successful switch from insulin therapy to treatment with pioglitazone in type 2 diabetes patients with residual beta-cell function: results from the PioSwitch study. Diabetes Obes Metab 2009; 11: 464-471.
132. Bell DS, Mayo MS. Improved glycemic control with use of oral hypoglycemic therapy with or without insulin. Endocr Pract 1998; 4: 82-85.